ArticleAmerican journal of translational research2025
Peripheral blood neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index values as prognostic predictors for non-small cell lung carcinoma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study.Frontiers in immunology · 2026Article
- Construction and validation of a prognostic prediction model for critically ill lung cancer patients based on respiratory functional reserve and systemic inflammatory characteristics.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate whether systemic inflammatory biomarkers - neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) - have prognostic value in patients with non-small cell lung carcinoma (NSCLC).
methodsIn this retrospective study, NLR, PLR, and SII levels were examined in 183 NSCLC cases. Correlations between these biomarkers and 3-year overall survival (OS) and progression-free survival (PFS) were assessed. Receiver operating characteristic (ROC) curves were used to evaluate predictive performance. Point-biserial correlation was applied to explore associations between each biomarker and 3-year OS/PFS, followed by multivariate analyses to identify independent prognostic factors.
resultsThe 3-year OS and PFS were 74.86% and 65.03%, respectively. Survivors and patients without progression had significantly lower NLR, PLR, and SII values than non-survivors and those with progression. ROC curve analysis showed moderate predictive accuracy for individual biomarkers (area under the curve [AUC]: 0.714-0.808 for OS; 0.635-0.754 for PFS), whereas their combination substantially enhanced prognostic discrimination (AUC=0.906 for OS; AUC=0.812 for PFS) (P<0.001). Further investigation demonstrated an inverse correlation between NLR, PLR, SII and 3-year OS/PFS (P<0.01). Multivariate analysis identified high NLR (≥3.57, OR=9.923), PLR (≥216.00, OR=9.978), and SII (≥969.50, OR=4.913) were independently associated with worse survival outcomes (P<0.05).
conclusionNLR, PLR, and SII are valuable predictors of survival in NSCLC. Integrating these biomarkers further improves prognostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.